This inventor holds 2 USPTO granted patents. Top assignees: Amphastar Pharmaceuticals, Inc., Eli Lilly and Company. Active years: 2019-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2025
Title: Claude A Piche: Innovator in Nasal Powder Formulations
Introduction
Claude A Piche is a notable inventor based in Verdun, Canada. He has made significant contributions to the field of pharmaceutical formulations, particularly in the treatment of hypoglycemia. With a total of 2 patents, his work has the potential to impact the lives of many individuals suffering from this condition.
Latest Patents
One of Claude A Piche's latest patents is a nasal powder formulation for the treatment of hypoglycemia. This invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration. It is particularly useful in treating severe hypoglycemia. The patent also outlines a method for making this powder formulation, along with devices and methods for its application. This innovative approach could revolutionize how hypoglycemia is managed, offering a more effective and accessible treatment option.
Career Highlights
Throughout his career, Claude A Piche has worked with prominent companies in the pharmaceutical industry. He has been associated with Amphastar Pharmaceuticals, Inc. and Eli Lilly and Company. His experience in these organizations has contributed to his expertise in developing effective medical formulations.
Collaborations
Claude A Piche has collaborated with several professionals in his field, including Sankaram B Mantripragada and Jo Jan Filip Van Betsbrugge. These collaborations have likely enriched his work and led to advancements in his research and inventions.
Conclusion
Claude A Piche is a distinguished inventor whose work in nasal powder formulations for hypoglycemia showcases his innovative spirit and dedication to improving healthcare solutions. His contributions are poised to make a significant difference in the treatment of this condition.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
